Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations

Cardiovascular Research

Volumn 103, Issue 2, 2014, Pages 248-257

  Witjas Paalberends, E Rosalie ^a   Güclü, Ahmet ^a,b   Germans, Tjeerd ^a   Knaapen, Paul ^a   Harms, Hendrik J ^a   Vermeer, Alexa M C ^c   Christiaans, Imke ^c   Wilde, Arthur A M ^c   DosRemedios, Cris ^d   Lammertsma, Adriaan A ^a   Van Rossum, Albert C ^a   Stienen, Ger J M ^a,e   Van Slegtenhorst, Marjon ^f   Schinkel, Arend F ^f   Michels, Michelle ^f   Ho, Carolyn Y ^g   Poggesi, Corrado ^h   Van Der Velden, Jolanda ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SYDNEY   (Australia)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hypertrophic cardiomyopathy; Mutation carriers; Myocardial efficiency; Sarcomere function; Sarcomere mutations

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM ION; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; CARDIAC MYOSIN; CARRIER PROTEIN; MYH7 PROTEIN, HUMAN; MYOSIN-BINDING PROTEIN C;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPLETION; DISEASE SEVERITY; ENERGY; ENERGY CONSUMPTION; FEMALE; GENE CONTROL; GENE MUTATION; HEART CONTRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE TENSION; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; MALE; MYOFILAMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOMERE; VERY ELDERLY; ACTIN FILAMENT; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHYSIOLOGY;

ACTIN CYTOSKELETON; ADULT; AGED; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYOCARDIAL CONTRACTION; MYOSIN HEAVY CHAINS; SARCOMERES;

EID: 84904330104     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu127     Document Type: Article

References (51)

1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemilogy and Prevention. Circulation 2006;113: 1807-1816 (Pubitemid 43958474)
2. Brigden W. Uncommon myocardial diseases: the non-coronary cardiomyopathies. Lancet 1957;273:1243-1249
3. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKennaW, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006
4. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008;19:104-110
5. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagege A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998;97:2230-2236 (Pubitemid 28265384)
6. Marian AJ, Salek L, Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med 2001;92:435-451 (Pubitemid 34184275)
7. Michels M, Soliman O II, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, Majoor-Krakauer D, Ten Cate FJ. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009;30:2593-2598
8. Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG, Seidman CE. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002;105:446-451 (Pubitemid 34141700)
9. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-1257 (Pubitemid 28216578)
10. Olson RE, Schwartz WB. Myocardial metabolism in congestive heart failure. Medicine 1951;30:21-41
11. Katz AM. Is the failing heart energy depleted? Cardiol Clin 1998;16:633-644 (Pubitemid 28509447)
12. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, PetersW, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-2196 (Pubitemid 27425822)
13. Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, Yacoub MH. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 1999;29:469-477 (Pubitemid 29271636)
14. Ashrafian H, Redwood C, Blair E,Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 2003;19:263-268 (Pubitemid 36507008)
15. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc.Res 2009;81: 412-419
16. Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest 2003;112:768-775 (Pubitemid 38057717)
17. He H, Javadpour MM, Latif F, Tardiff JC, Ingwall JS. R-92L and R-92W mutations in cardiac troponin T lead to distinct energetic phenotypes in intact mouse hearts. Biophys J 2007; 93:1834-1844 (Pubitemid 47403322)
18. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:1775-1783 (Pubitemid 28198508)
19. Luedde M, Flogel U, Knorr M, Grundt C, Hippe H-J, Brors B, Frank D, Haselmann U, Antony C, Voelkers M, Schrader J, Most P,Lemmer B, Katus HA, Frey N. Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J Mol Med 2009;87:411-422
20. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K,Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-1782 (Pubitemid 36584252)
21. Jung WI, Hoess T, Bunse M, Widmaier S, Sieverding L, Breuer J, Apitz J, Schmidt O, van Erckelens F, Dietze GJ, Lutz O. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation 2000;101:121
22. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ. 31PNMRspectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97:2536-2542 (Pubitemid 28294500)
23. Timmer SA, Germans T, Brouwer WP, Lubberink M, van der Velden J, Wilde AA, Christiaans I,Lammertsma AA, Knaapen P, van RossumAC. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail 2011;13: 1283-1289
24. Potma EJ, Stienen GJM, Barends JP, Elzinga G. MyofibrillarATPase activity and mechanical performance of skinned fibres from rabbit psoas muscle. J Physiol 1994;474:303-317 (Pubitemid 24048341)
25. Van der Velden J, Moorman AF, Stienen GJM. Age-dependent changes in myosin composition correlate with enhanced economy of contraction in guinea-pig hearts. J Physiol 1998;507:497-510 (Pubitemid 28135199)
26. Narolska NA, van Loon RB, Boontje NM, Zaremba R, Penas SE, Russell J, Spiegelenberg SR, Huybregts MA, Visser FC, de Jong JW, van der Velden J, Stienen GJM. Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res 2005;65:221-229 (Pubitemid 40038495)
27. Potma EJ, van Graas IA, Stienen GJM. Effects of pH on myofibrillar ATPase activity in fast and slow skeletal muscle fibers of the rabbit. Biophys J 1994;67:2404-2410 (Pubitemid 24369664)
28. Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, Kofoed KF, Weismueller S, Czernin J, Phelps ME, Schelbert HR. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 1998;39:272-280 (Pubitemid 28114517)
29. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP, Lammertsma AA, Visser FC. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115:918-927 (Pubitemid 46294732)
30. Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten CF, Germans T, Carrier L, Sadayappan S, Van SM, Zaremba R, Foster DB, Murphy A, Poggesi C, dos Remedios CG, Stienen GJM, Ho CY, Michels M, van der Velden J. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 2013; 112:1524-4571
31. Witjas-Paalberends ER, Piroddi N, Stam K, van Dijk SJ, Oliviera VS, Ferrara C, Scellini B, Hazebroek M, Ten Cate FJ, Van SM, Dos RC, Niessen HW, Tesi C, Stienen GJM, Heymans S, Michels M, Poggesi C, Van der Velden J. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res 2013;99:432-441
32. Shub C, Klein AL, Zachariah PK, Bailey KR, Tajik AJ. Determination of left ventricular mass by echocardiography in a normal population: effect of age and sex in addition to body size. Mayo Clin Proc 1994;69:205-211 (Pubitemid 24085951)
33. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232-2239 (Pubitemid 44789498)
34. Van Dijk SJ, Dooijes D, Dos RC, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, Ten Cate FJ, Stienen GJM, Van der Velden J. Cardiac myosin-binding protein Cmutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009;119:1473-1483
35. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009;105:219-222
36. BeckerKD, Gottshall KR, Hickey R, Perriard JC,Chien KR. Point mutations inhuman beta cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: an ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assemb. J Cell Biol 1997;137:131-140 (Pubitemid 27167301)
37. De Tombe PP, Stienen GJM. Protein kinase A does not alter economy of force maintenance in skinned rat cardiac trabeculae. Circ Res 1995;76:734-741
38. HoskinsAC, Jacques A, Bardswell SC, McKenna WJ, Tsang V, dos Remedios CG, Ehler E, Adams K, Jalilzadeh S, Avkiran M, Watkins H, Redwood C, Marston SB, Kentish JC. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J Mol Cell Cardiol 2010;49:737-745
39. Kraft T, Witjas-Paalberends ER, Boontje NM, Tripathi S, Brandis A, Montag J, Hodgkinson JL, Francino A, Navarro-Lopez F, Brenner B, Stienen GJM, Van der Velden J. Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol 2013;57:13-22
40. Van Dijk SJ, Paalberends ER, Najafi A, Michels M, Sadayappan S, Carrier L, Boontje NM, Kuster DW, Van SM, Dooijes D, Dos RC, Ten Cate FJ, Stienen GJM, Van der Velden J. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail 2012;5:36-46
41. Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol 2001;536:583-592 (Pubitemid 32976137)
42. Chandra M, Tschirgi ML, Tardiff JC. Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ Physiol 2005;289: 2112-2119
43. Keller DI, Coirault C, Rau T, Cheav T,Weyand M, Amann K, Lecarpentier Y, Richard P, Eschenhagen T, Carrier L. Human homozygous R403Wmutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 2004;36:355-362 (Pubitemid 38316940)
44. Brenner B. Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci USA 1988;85:3265-3269
45. Poggesi C, Tesi C, Stehle R. Sarcomeric determinants of striated muscle relaxation kinetics. Pflugers Arch 2005;449:505-517 (Pubitemid 40543645)
46. Belus A, Piroddi N, Scellini B, Tesi C, Amati GD, Girolami F, Yacoub M, Cecchi F, Olivotto I, Poggesi C. The familial hypertrophic cardiomyopathy- associated myosin mutationR403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol 2008;586:3639-3644
47. Esposito A, De Cobelli F, Perseghin G, Pieroni M, Belloni E, Mellone R, Canu T, Gentinetta F, Scifo P, Chimenti C, Frustaci A, Luzi L, Maseri A, Maschio AD. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging. Heart 2009;95:228-233
48. Hollingsworth KG, Blamire AM, Keavney BD, Macgowan GA. Left ventricular torsion, energetics, and diastolic function in normal human aging. Am J Physiol Heart Circ Physiol 2012;302:885-892
49. Schocke MF, Metzler B, Wolf C, Steinboeck P, Kremser C, Pachinger O, Jaschke W, Lukas P. Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI). Magn Reson Imaging 2003;21:553-559 (Pubitemid 36899089)
50. Abozguia K, Elliott P, McKennaW, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H,Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010;122:1562-1569
51. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Rev 2007;25:76-97